U.S. lawmakers seek pricing info on PTC Therapuetics' Duchenne drug

(Reuters) - Two U.S. lawmakers sent a letter on Wednesday to PTC Therapeutics Inc, seeking information about the drugmaker's pricing strategy for its recently acquired muscle-wasting disorder drug.